Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose @entity2857 for metastatic XXXX .

@entity13969 @entity1 @entity5 @entity29513 @entity584 @entity2857 @entity1358 @entity3 @entity3027 @entity1851
BACKGROUND: @entity3027 is one of the central agents in immunotherapy for @entity1358 ( @entity1358 ). It acts by binding to the @entity13969 ( @entity13969 ). We previously reported that increased @entity5 expression of @entity29513 mRNA was associated with the metastatic potential and progression of @entity1358 , as well as with a poor response of metastatic @entity1358 to @entity3027 therapy. This study investigated the influence of serum @entity29513 in @entity1358 @entity1 . METHODS: We measured serum @entity29513 mRNA levels and quantified @entity13969 mRNA expression in paired @entity5 and non- @entity5 tissues from the surgical specimens of 66 consecutive @entity1358 @entity1 by the real-time reverse transcription polymerase chain reaction (RT-PCR). We also measured phosphorylated @entity584 (Ser-473) and phosphorylated-S6 ribosomal protein (Ser-235/236) proteins levels in paired @entity5 and non- @entity5 tissues of @entity1 with metastatic @entity1358 by Western blotting. RESULTS: The serum level of @entity29513 mRNA was not associated with its @entity5 tissue level. Serum @entity29513 mRNA was positively correlated with @entity5 size (P  <  0.05), but not with @entity5 grade, pT stage, @entity3 , microscopic vascular invasion, or serum @entity1851 . Serum levels of @entity29513 mRNA were significantly higher in @entity1 with a good response to @entity3027    @entity2857 than in those with a poor response (P  <  0.0001). Tumor tissue @entity29513 mRNA levels and phosphorylated-S6 ribosomal protein (Ser-235/236) levels were associated with metastatic potential (P  <  0.001 and P  <  0.01, respectively), and @entity1 with a low @entity29513 mRNA level and low phosphorylated @entity584 (Ser-473) protein level in the @entity5 showed a good response to @entity3027    @entity2857 ( @entity3027    Sor: CR-PR) (P  <  0.01 and P  <  0.05, respectively). Kaplan-Meier survival analysis showed that a higher serum @entity29513 mRNA level was associated with longer overall survival of treated @entity1 (P  <  0.05), while a higher @entity5 tissue @entity29513 mRNA level was related to shorter overall survival (P  <  0.01). CONCLUSIONS: Our findings suggest that a high serum level of @entity29513 mRNA may be a useful marker for predicting the response of metastatic @entity1358 to @entity3027    @entity2857 therapy.
